LifeMD, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LifeMD, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $12.47M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $8.32M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.68M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.24M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.22M | May 24, 2017 |
| FY2015 | Dec 31, 2014 | $714.2K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $808.4K | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $673.8K | Mar 28, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.06M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $154.82M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $152.55M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $119.03M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $92.88M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $37.29M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $12.47M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $42.5K | Mar 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.00M | Apr 2, 2018 |
| FY2016 | Dec 31, 2016 | $5.00M | May 24, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.34M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $133.38M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $133.65M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $100.37M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $74.88M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $28.43M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $9.94M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.33M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.66M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.29M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.35M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($21.41M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($20.60M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($45.54M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($60.90M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($58.65M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($3.14M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.24M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.21M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.11M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.67M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($20.40M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($14.49M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($43.45M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($54.30M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($57.82M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($2.89M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.06M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.23M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.17M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $23.9K | May 24, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.28M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $17.51M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $8.82M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($22.94M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($33.09M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($12.13M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $251.4K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($905.5K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($817.2K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($407.9K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.46M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $203.8K | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $366.6K | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $247.4K | Mar 22, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.41M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $76.10M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $58.48M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $25.67M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $49.92M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $13.40M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.45M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.62M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.26M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $789.8K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.25M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $83.65M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $52.91M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $32.97M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $24.10M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $14.22M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $4.58M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.80M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $641.0K | Apr 1, 2019 |
| FY2015 | Dec 31, 2015 | $267.5K | Mar 30, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.16M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($9.08M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.51M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($11.40M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $22.74M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($2.30M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($988.2K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $897.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $881.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($355.2K) | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $8.00M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 22, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($228.60M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($239.85M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($214.27M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($190.56M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($141.92M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($80.15M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($16.59M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($12.14M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($10.90M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($9.69M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $35.00M | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $33.15M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $3.96M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $41.33M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $9.18M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.11M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $180.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $141.4K | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $182.6K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $233.0K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.66M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 42.19M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 38.26M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 31.45M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 30.60M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 23.33M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 10.58M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 45.27M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 43.98M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 35.25M | Apr 2, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $10.8K | Mar 30, 2016 |